Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Study limitation reported by the research below: “Study publication date (2026-09-14) is recent; this is a newly published paper and independent replication has not yet been assessed.”